Note 6 - Inventory

9 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Inventory Disclosure [Text Block]

6. Inventory, Net

The components of inventory, net as of September 30, 2022 and December 31, 2021 are as follows:

	September 30, 2022			December 31, 2021
Materials	$	193,806		$	50,000
Finished goods		133,006			101,155
Reserve for obsolete finished goods		(133,006	)		—
Total inventory, net	$	193,806		$	151,155

During the nine-month period ended September 30, 2022, we reserved $133,006 of finished goods inventory based on our expectation that this inventory will expire before it can be sold or used in clinical trials. This transaction was recorded in reserve for expiring inventory in the condensed consolidated statements of operations. No such inventory reserves were recorded during the nine-month period ended September 30, 2021.

During the three-month periods ended September 30, 2022 and 2021, we allocated $45,696 and $0, respectively, of finished goods inventory for use in clinical trials. During the nine-month periods ended September 30, 2022 and 2021, we allocated $45,696 and $10,404, respectively, of finished goods inventory for use in clinical trials. These transactions were recorded in research and development expense in the condensed consolidated statements of operations.